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ABSTRACT:
High expression of Rac small GTPases in invasive breast ductal carcinoma is 
associated with poor prognosis, but its therapeutic value in human cancers is not 
clear. The aim of the current study was to determine the response of human primary 
breast cancers to Rac-based drug treatments ex vivo.
Three-dimensional organotypic cultures were used to assess candidate 
therapeutic avenues in invasive breast cancers. Uniquely, in these primary cultures, 
the tumour is not disaggregated, with both epithelial and mesenchymal components 
maintained within a three-dimensional matrix of type I collagen. EHT 1864, a small 
molecule inhibitor of Rac GTPases, prevents spread of breast cancers in this setting, 
and also reduces proliferation at the invading edge. Rac1+ epithelial cells in breast 
tumours also contain high levels of the phosphorylated form of the transcription factor 
STAT3. The small molecule Stattic inhibits activation of STAT3 and induces effects 
similar to those seen with EHT 1864. Pan-Rac inhibition of proliferation precedes 
down-regulation of STAT3 activity, defining it as the last step in Rac activation during 
human breast cancer invasion. 
Our data highlights the potential use of Rac and STAT3 inhibition in treatment 
of invasive human breast cancer and the benefit of studying novel cancer treatments 
using three-dimensional primary tumour tissue explant cultures.
INTRODUCTION
In recent years there has been a growing 
appreciation that developing new effective treatments may 
be facilitated by experimental systems that replicate the 
multi-component tumour environment [1, 2]. Furthermore, 
there are serious doubts regarding the relevance of drug 
testing in established cancer cell lines and transfer of 
results to the clinic [3]. We have developed a three-
dimensional culture system that allows maintenance of 
complex breast cancer specimens explanted ex vivo for 
up to four weeks after surgical resection in a supporting 
matrix of exogenous stromal type I collagen [4, 5]. These 
ex vivo cultures offer a relatively rapid and quantitative 
avenue to explore mechanisms of tumour spread and 
evaluate new treatments. 
The metastatic potential of cancer cells is 
orchestrated by cell-cell adhesion, cell-matrix adhesion, 
protrusion and contractility, all of which require 
appropriate regulation and dynamics of the cytoskeleton 
[6]. The Ras-like Rho family GTPases are key regulators 
of all of these cellular processes due to their interaction 
with multiple downstream targets. The ability of Rac1 to 
induce metastasis has been closely linked to mesenchymal 
type motility in cancer cell lines [7-9]. This is likely to 
be due to Rac activity near the cell leading edge and 
subsequent disruption of cellular organization [10, 11]. 
Nonetheless, Rac activity must be tightly regulated in 
order to maintain normal epithelial cell junction formation, 
polarization and proliferation [12-14]. 
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Rac activation can induce invasion and metastasis 
of breast cancer cell line models in vitro and in vivo [15]. 
Over-expression of Rac1 and Rac3 GTPases has been 
noted in several small cohorts of breast cancers [16-18] 
and it has been suggested that they may have a role in 
resistance to endocrine treatment [19, 20]. In breast 
cancer, this mechanism is best described in the context of 
HER2 over-expression. As a result of TGFβ stimulation, a 
complex comprising HER2, Vav2, Rac1, Pak1, actin and 
actinin is formed at cell protrusions [21]. The induction of 
Rac1 activity by the guanine nucleotide exchange factor 
(GEF) Vav2 causes invasion and contributes to cancer cell 
survival [20] and disruption of correct polarisation of the 
breast epithelium [22]. Other GEFs may also stimulate 
Rac1 downstream of HER2, including P-REX1 [22]. Up-
regulation of Rac1 activity by P-REX1 and Tiam1 GEFs 
has been described independently of tumour HER2 status 
[21], although the latter finding is disputed [23]. 
Across a panel of 51 established breast cell lines 
[24], both normal and malignant, similar, detectable 
levels of Rac1 mRNA were observed. The levels of Rac2 
and Rac3 transcripts were more variable, being reliably 
detected in less than half of the cell lines (our unpublished 
observations). Studies of Rac function using cell lines 
already have contributed to understanding of initiation of 
malignant transformation, but do not inform how intact 
human tumours may respond to therapeutic intervention 
[25]. We previously reported that the majority of invasive 
human breast cancers continue to express E-cadherin and 
β-catenin correctly at the cell membrane junctions [26]. 
Therefore, pan-Rac inhibition of the whole, intact breast 
tumour explant could potentially bring about apparently 
conflicting effects on epithelial versus mesenchymal cells. 
It may lead to destruction of epithelial junctions enabling 
Figure 1: RAC1 is more highly expressed in breast cancer and is associated with poor prognosis.  (A) Box plots 
demonstrating that invasive ductal carcinomas (IDC) have higher RAC1 expression than normal breast ducts, but range is similar. (B-C) 
RAC1 is not associated with estrogen receptor alpha (ER) status or histological grade of primary breast tumours. (D) Kaplan-Meier survival 
curves for all breast cancer patients with available data in the meta-dataset show that high levels of RAC1 expression are associated with 
poorer prognosis (n=1654). RAC1 expression levels were divided into low and high groups at the median. (E) An example of invasion ex 
vivo: 3D reconstruction of optical projection tomography of a representative ER+ HER2- tumour. The original tumour material is in blue 
(autofluorescence) and invading epithelial tumour cells are in green (cytokeratin labelled). (F) Immunohistochemistry showing that cells 
invading ex vivo express Rac1 protein (upper panel) and its short isoform Rac1b (lower panel). Rac1 and Rac1b are expressed in both 
tumour epithelial (arrowheads) and mesenchymal (arrows) invading cells. Images are from a representative ER- HER2-  tumours. Lower 
magnification images are in Figure S2. Bars, 50 μm. The dotted lines show border between original tumour explant (OT) and surrounding 
collagen (SC). Brown staining indicates cells positive for Rac1 and Rac1b staining.
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invasiveness, while blocking mesenchymal motility. 
In this study we examine the response of authentic 
primary breast cancers to Rac-based drug treatments. 
We show that invasive breast cancers are responsive to 
exposure to EHT1864, a water soluble pan-Rac inhibitor. 
Consequently, Rac inhibition blocks a key down-
stream effector, the Signal Transducer and Activator of 
Transcription-3 (STAT3) transcription factor. We show 
that Rac and STAT3 inhibition regimens are effective at 
blocking tumour invasion ex vivo, independently of known 
clinical biomarkers such as histological grade and ER 
status.
RESULTS
Rac1 is over-expressed in invasive human breast 
cancer
In order to determine whether Rac1 protein might 
be a viable therapeutic target in breast cancer, we analysed 
its mRNA expression levels in published gene expression 
datasets. RAC1 was found to be significantly higher 
expressed in breast tumours than in normal breast tissue 
(Figure 1A). We then used a meta dataset of 2999 primary 
breast tumours (see Methods) to explore whether RAC1 
expression associated with particular subtypes of breast 
tumours. There was no significant variation in RAC1 
levels with grade or ER status (Figure 1B-C). RAC1 was 
significantly higher and associated with poor prognosis in 
HER2 (ERBB2) over-expressing tumours, although the 
range of RAC1 expression was similar between HER2+ 
and HER2- tumours (Figure S1). Importantly, high levels 
of RAC1 were associated with late recurrence (Figure 
1D). Overall, these data suggest that RAC1 may represent 
a therapeutic target with broad potential in breast cancer, 
because it does not show a strong association with 
particular patient groups.
We have recently succeeded in establishing a robust 
system for long-term culture of human breast cancer 
explants, successfully growing >90% tumours of all major 
sub-types [4, 5]. In these cultures, primary breast cancer 
biopsies from invasive breast cancers are explanted into 
Figure 2: Rac inhibition ex vivo blocks tumour invasion. (A) Tumour invasion into surrounding collagen is readily detectable 
using H&E staining (upper panel). Continuous Rac inhibition with EHT1864 for 14d (bottom panel) results in blockage of invasion 
beyond the original tumour material (black outline) and extensive cell death: Bars, 50 µm. Outgrowth of tumour cultures were categorised 
following treatment with EHT 1864 or vehicle control, as follows: (B) continuous exposure from start of culture, or (C) exposure of existing 
outgrowths, 10d after start of culture. All inhibitor treatments lasted 14d. Results were obtained from light microscopy examination and 
subsequently confirmed by H&E staining. Tumour biomarkers shown were determined by a pathologist as part of clinical practice.
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the centre of a type I collagen matrix. From each tumour 
cultured ex vivo, 80%-100% of explants are viable and 
display variable degrees of cellular spread into the 
surrounding collagen [4]. Growth in mammary epithelial 
media occurs in all three dimensions, as demonstrated 
optical projection tomography (Figure 1E; cytokeratin 
labels epithelial structures (green) invading from the 
original biopsy material into the surrounding collagen). 
We found that in many breast cancers grown ex vivo, 
both Rac1 and its constitutively active isoform Rac1b, 
are preferentially expressed in invading cells (Figures 1F 
and S2; n=6) when assessed by immnunohistochemistry. 
Importantly, both isoforms are expressed in tumour 
epithelial and mesenchymal cells, indicating wide spread 
Rac activity. 
Rac inhibition blocks the spread of human breast 
cancer 
We used EHT 1864, a water soluble pan-Rac 
inhibitor [27], to determine the value of Rac inhibition 
in the explant model. EHT1864 exhibits high affinity 
binding to Rac1, as well as the related Rac1b, Rac2, and 
Rac3 isoforms, inhibiting their activity via a mechanism 
that involves guanine nucleotide displacement [27]. EHT 
1864 has been used previously in cell line models in 
2D, especially in the context of Rac1 activity [19, 28]. 
Continuous treatment of breast cancer explant cultures 
with EHT 1864 for 14 days resulted in complete block of 
invasion into the surrounding collagen, and wide spread 
cell death (Figure 2A). We characterised the effects 
of Rac inhibition in two regimens: in the first regimen, 
Figure 3: Rac inhibition with of tumour outgrowth ex vivo results in block of proliferation and cell death. (A) The effect 
of treatment with EHT 1864 or vehicle control on outgrowth of tumour cultures was obtained from light microscopy examination and 
subsequently confirmed by H&E staining. Shown are reperentative results from ER- HER2- tumour explant culture lasting 14d (n=4). Note 
that continuous EHT1854 treatment reduces viable outgrowth (regimen #4) in comparison to short-treatment (#2) or vehicle control (#1). 
Rac inhibition of tumour invasion is accompanied with induction of apoptosis as detected by immunohistochemistry for cleaved caspase-3 
(B) and block of proliferation, detected by Ki67 staining (C). (D) E-cadherin levels are unchanged ex vivo. Shown here representative 
images from a single ER- HER2-  tumour, (left panel) without or (right panel) with EHT 1864. The dotted lines show border between 
original tumour explant (OT) and surrounding collagen (SC). Bars, 50 μm.
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explants from the same cancer were divided randomly to 
equally sized treatments groups and treated continuously 
for 14 days (Figure 2B). In the second regimen, explant 
cultures were left to grow out for 10 days, and then 
divided randomly to treatment groups for a further 14 days 
(Figure 2C). Both regimens resulted in almost complete 
elimination of tumour outgrowth into the surrounding 
collagen. Using logistic regression, Rac inhibition with 
EHT 1864 exhibited an odds ratio of 0.01 of outgrowth 
compared with vehicle (p < 0.0001, 95% CI 0.003 to 
0.04).
Rac inhibition blocks proliferation and induces 
apoptosis in human breast cancers
Tumour outgrowth resumed if Rac inhibition 
was removed after 3 days of treatment (Figure 3A; 4 
independent experiments), indicating that EHT 1864 
treatment is not solely as a result of cytotoxicity. We 
therefore examined what down-stream effects on apoptosis 
(assessed by demonstration of cleaved caspase-3) and 
proliferation (as assessed by Ki67). The number of cells 
undergoing cell death at the experimental endpoint rose 
from a basal level of <20% in vehicle-treated tumours 
[5] to 30%-50% of cells treated with EHT 1864. These 
cells were found predominantly around the periphery of 
the original tumour explant (Figure 3B). Vehicle-treated 
tumours have a wide range of proliferation from 10% 
to 60% of cells [5], but exposure to EHT 1864 reduced 
proliferation to less than 5% (Figure 3C). Interestingly, 
levels of E-cadherin expression were very similar with or 
without EHT 1864 treatment (Figure 3D).
STAT3 is a down-stream mediator of Rac activity 
in breast cancer spread
A cell line 3D model was established to assess the 
potential contribution of Rac1 down-stream targets in 
epithelial cell invasion. We modified our collagen-based 
invasion culture [29] using the HCC1954 cell line, which 
invades in organised fashion in vivo [30]. In 3D culture, 
HCC1954 cells express proteins such as E-cadherin in a 
similar manner to this observed in tumour cells cultured 
ex vivo (Figure S3). In the absence of serum, HCC1954 
cells invade collectively (Figure S4A). Treatment of the 
cell line culture with EHT 1864 resulted in rapid (<24 
h) inhibition of invasion and appearance of apoptotic 
cells (Figures S5A). Surviving HCC1954 cells were still 
positive for Ki67, a marker of proliferation (Figure S5B). 
The effects of pan-Rac inhibition in the cell line model 
could not be replicated by inhibitors against many known 
Rac downstream mediators: JNK (SP600125), PAK (IPA3) 
or p38α (SB203580) (data not shown). 
Another well established Rac1 target is 
Figure 4: STAT3 signaling is downstream of Rac activity during invasion of human breast cancer. (A) Immunohistochemistry 
shows that Rac1 protein expression (left panel) and STAT3 phosphorylation on Ser727 (right panel) frequently coincide in human breast 
cancer. Epithelial cells which are Rac1+ pSTAT3- are also present. (B) STAT3 phosphorylation is associated with invasion ex vivo and is 
down regulated by Rac inhibition (right panels; inhibition as in Figure 2). Identical patterns are seen with the STAT3 transcriptional target 
Survivin, ex vivo (C). Even after exposure to EHT 1864, a few cells are still positive for phospho-STAT3 and Survivin (arrows in B and C). 
Images are shown from a representative ER- HER2- tumour. Lower magnification images are in Figure S6. The dotted lines show border 
between original tumour explant (OT) and surrounding collagen (SC). Bars, 50 µm.
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phosphorylation of STAT3 at Ser727 is [31]. We examined 
Rac1 and phospho-Ser727 STAT3 levels by antibody 
staining in human breast tumours (n=6). Patterns Rac1 and 
phospho-Ser727 STAT3 staining are similar, especially 
in epithelial cells (Figure 4A). Phospho-Ser727 STAT3 
staining is abundant in the invading cells ex vivo (Figure 
4B and S6A). In the HCC1954 model, Rac inhibition 
resulted in reduction in phospho-Ser727 STAT3 (Figure 
S6A). Survivin, a well established target of STAT3 
transcriptional activity [32], is also down-regulated by 
EHT 1864 treatment of cell line cultures (Figure S7B). 
Some HCC1954 cells survived Rac inhibition for 24 h, 
retaining both phospho-Ser727 STAT3 and Survivin 
(Figure S5, arrows).
Block of proliferation by Rac inhibition ex vivo 
precedes down-regulation of STAT3 activity 
We tested whether long-term Rac inhibition also 
blocks STAT3 activity in the explant tumour cultures. The 
intensity of phospho-Ser727 STAT3 staining ex vivo was 
greatly reduced by EHT 1864 (Figure 4B). Consistent with 
STAT3 activity down-stream of Rac, EHT 1864 treatment 
resulted in down-regulation of Survivin protein expression 
(Figures 4C). Interestingly, cells initially surviving Rac 
Figure 5: The early cellular response to Rac inhibition ex vivo. (A) Tumour explants were grown ex vivo for 14 days prior 
to inhibitor treatment in order to define events induced by a single post-growth treatment. Immunohistochemistry suggest that STAT3 
phosphorylation (vehicle, left panels) is down regulated by EHT 1864 (middle panels) or Stattic (right panels) within 72 h of treatment. 
(B) Wide spread apoptosis is detected in Stattic treated cultures (right panel) and to lesser extent in EHT 1864 treated cultures (middle 
panel). Effects on proliferation are shown by staining with the marker Ki67 and (C) the cell cycle protein cyclin D1 (D): reduced in EHT 
1864 (middle panel) or Stattic (right panel) exposed cultures). The dotted lines show border between original tumour explant (OT) and 
surrounding collagen (SC). Bars, 50 μm. Quantification is shown for percent of positive invading cells from two preparations per treatment, 
all originating from the same tumour.
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inhibition retained both nuclear localization of phospho-
Ser727 STAT3 and Survivin ex vivo (arrows).
STAT3 may be indirectly controlled by Rac via an 
autocrine or paracrine signal [33, 34]. We examined if 
there are short-term effects of Rac inhibition preceding 
changes in STAT3 activity ex vivo. The role of STAT3 
downstream of Rac activation was confirmed using Stattic, 
an inhibitor of dimerization and nuclear translocation of 
STAT3 preventing its constitutive activation [35]. After 
one round of treatment with EHT 1864, only a partial 
reduction in phospho-Ser727 STAT3 and Survivin staining 
can be observed by immunohistochemistry (Figure 5A and 
not shown). The rapid induction of apoptosis by STAT3 
inhibition in comparison to Rac inhibition, supports 
a more direct effect of STAT3 inhibition (Figure 5B). 
Importantly, proliferation within the invading cells is 
greatly reduced by both inhbitors (Figure 5C), suggesting 
most likely through down-regulation of cyclin D1 (Figure 
5D), a known Rac1 and STAT3 target [36-39].  The 
dramatic induction of apoptosis by Stattic is even more 
pronounced than this caused by EHT 1864, in line with 
previous reports in breast cancer cell lines [35, 40-42].
Stattic treatment has similar long-term effects to 
those seen with EHT 1864 on tumour invasion ex vivo 
(Figure 6). Using logistic regression, STAT3 inhibition 
with Stattic exhibited an odds ratio of 0.003 (p < 0.0001, 
95% CI 0.001 to 0.018) compared with vehicle.
DISCUSSION
Although endocrine (for ER+ tumours), cytotoxic 
chemotherapy (for ER- tumours) or Herceptin (for HER2+ 
tumours) regimens are successful treatments for some 
breast cancer patients, mortality due to recurrence of 
Figure 6: STAT3 inhibition blocks tumour outgrowth ex vivo. Outgrowth of tumour cultures were categorised following treatment 
with Stattic or vehicle control, as follows: (A) continuous exposure from start of ex vivo culture, or (B) exposure of existing outgrowths, 
10d after start of culture. All inhibitor treatments lasted 14d. Results were obtained from light microscopy examination and subsequently 
confirmed by H&E staining. Tumour biomarkers shown were determined by a pathologist as part of clinical practice.
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cancers which develop drug resistance and metastases 
is still common [43]. Therefore, identification of novel 
treatment for metastatic breast cancer is important 
to enhance long term patient survival [44]. As direct 
measurements of enzymatic activity in human tumours are 
difficult and possibly inaccurate due to clinical constrains 
in sample collection, other methods are need to evaluate 
such novel treatments.
The over-expression of Rho GTPases has previously 
been implicated in the promotion of various cancer types 
[16, 45]. It is also well established that Rho, Cdc42 and 
particularly Rac1 have critical roles in experimental 
tumour metastasis [33, 38]. It is usually thought that Rac 
activity in cancer is associated with the loss of epithelial 
cell-cell junctions and gain of mesenchymal phenotype 
[46]. Many signaling pathways lie downstream of Rac 
proteins, although their relationship to malignancy is not 
always clearly understood. These include the activation 
of JNK and p38 proteins [47], as well as non-canonical 
(β-catenin-independent) WNT signaling pathways [48]. It 
has been suggested that the constitutively active isoforms 
Rac1b and Rac3 show pathway preference, which is 
distinct from that of the GEF-dependent isoforms Rac1 
and Rac2 [8, 16, 49]. 
Here, we have shown that the spread of breast 
tumours in an ex vivo model is sensitive to Rac inhibition. 
This 3D culture model recapitulates epithelial invasion 
of human breast cancer tumours in vivo, in particular 
maintaining E-cadherin membrane expression, unlike 
invasive breast cancer cell lines [26, 29]. Recent evidence 
links proliferation and invasion to the spread of cancer, 
both of which are inhibited in our model system upon 
EHT 1864 exposure [33, 50]. Moreover, a study in mouse 
melanoblasts suggested a role for Rac1 in proliferation 
of motile cells, although the exact mechanism was not 
identified [51]. 
Our experiments demonstrate that an approach 
involving pan-Rac inhibition has the potential to be 
applied to the clinic. In the current study, inhibition 
of all Rac isoforms by EHT1864 in explants of intact 
primary cancers prevented spread into collagen, reduced 
proliferation and subsequently caused apoptosis. The 
reduction in cyclin D1 levels by Rac inhibition did not 
result in greater invasiveness, as reported in MDA-
MB-231 cells [52].  EHT 1864 blocks the constitutively 
active Rac1b and Rac3 isoforms [27], unlike the more 
widely used Rac GEF inhibitor NSC23766. EHT 1864 
is likely to be superior to using a Rac GEF inhibitor, 
which will not have any effect on the Rac1b or Rac3, 
long considered to be associated with breast cancer 
aggressiveness [8, 16]. To date, a range of in vitro and in 
vivo models has not reported any significant cytotoxicity 
associated with EHT 1864. This represents a therapeutic 
opportunity as breast cancers should have higher over-all 
Rac activity than this of the surrounding normal breast. 
We have demonstrated, at the breast cancer tissue 
level, a link between STAT3 and Rac proteins. STAT3 
is a critical transcription factor regulating cell death 
during breast involution [53], but it can also function as 
an oncogene [39]. STAT3 activity (in absence of STAT5 
activity) has been shown previously to be present in 40% 
of human breast cancers and has been linked to higher 
grade and lymph node metastasis [54]. STAT3 inhibition 
has a clear anti-tumour effect as demonstrated by a variety 
of reagents [42, 55]. It is conceivable that disruption of 
the feedback loop between Rac1 and E-cadherin adherens 
junctions could lead to aberrant STAT3 activation in breast 
cancer [56]. 
The current study suggests that invasion of breast 
cancer is associated with up-regulation of Rac and STAT3 
activity. The challenge now is to understand which 
breast cancer patients may be most suited for Rac-based 
treatment, once a drug is available for human use. Our 
finding that patients with HER2high RAC1high tumours 
have the worst prognosis, suggests that Rac targeting in 
the clinic may particularly benefit patients with HER2+ 
tumours. This is supported by recent experiments in 
mice suggesting that gp130/STAT3 signalling is critical 
in HER2-induced tumourigenesis [57]. Our findings 
that even after exhaustive Rac inhibition in intact breast 
tumour, STAT3 activity is detected in rare live cells 
suggest that optimal treatment may require a combination 
of drugs inhibiting Rac and STAT3 activities.
MATERIALS AND METHODS
Gene Expression Analysis
Raw .cel files from seventeen Affymetrix U133A/
plus 2 gene expression datasets were downloaded from 
NCBI GEO (GSE12276, GSE21653, GSE3744, GSE5460, 
GSE2109, GSE1561, GSE17907, GSE2990, GSE7390, 
GSE11121, GSE16716, GSE2034, GSE1456, GSE6532, 
GSE3494 and GSE19615) or the caBIG (geral-00143) 
repositories, summarised with Ensembl alternative CDF 
[58] and normalised with RMA [59], before integration 
using ComBat [60] to remove dataset-specific bias as 
previously described [61]. The most conservative measure 
available of recurrence-free, disease-free and distant-
metastasis-free survival was used. Cox proportional 
hazards regression was performed using SPSS version 14.
Ethical approval
The use of tissue from invasive breast cancer treated 
at the Edinburgh Breast Unit at the Western General 
Hospital was approved by the Lothian Research Ethics 
Committee (06/S1103/65). The clinical parameters of all 
tumours used in this study are listed in Table S1.
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Collagen-based 3D cultures
The set-up of collagen type I-based cultures, ex vivo 
and cell line, was described in detail previously [4, 29].
For cell line cultures, 75 μL or 150 μL cell-Matrigel 
plugs were made using 2 x 106 cells/ml and 5mg/ml 
Matrigel (BD bioscience), in a U-shaped 96-well plate. 
After overnight incubation, cell plugs were carefully 
removed from their 96-well plate and embedded in 1 ml 
of rat collagen I (1 mg/ml) in a 24-well plate or 2 ml of 
collagen in a 12-well plate. These cultures were incubated 
for a further 1 h and then carefully freed from the edges 
of the well (to allow contraction of the collagen) and 
supplemented with 1 ml or 2 ml RPMI media (without 
serum). The cells were then left to invade. Media was 
changed every 3-5 days. Rac inhibitor (EHT 1864, Tocris 
#3872, 20 μM) or STAT3 inhibitor (Stattic, Tocris #2798, 
10 μM) were added at the last 24 h or 96 h.
For ex vivo cultures, breast tumour biopsy materials 
(cut to 1mm pieces) were explated instead of Matrigel 
plugs in a 24-well plate format. The media used ex vivo is 
complete MEGM (Lonza). Continuous inhibitor treatment 
lasted between days 1-14. For late addition assays, assays 
with viable growth at day 6 or 8 (as observed using a light 
microscope) were divided to equal size groups (> 4 assays 
per treatment). Treatment with inhibitor or appropriate 
vehicle control lasted for subsequent 12 days. Inhibitors 
were added at concentrations as above every 3 days. In 
experiments represented in Figure 4, tumours (n=4) were 
allowed to grown for 7-14 d prior to inhibitor treatment 
lasting 3 additional days. Quantification of positive 
nuclei in invading cells was performed on entire sections 
obtained from the same tumour (>90 cells/preparation).
To terminate all experiments, cultures were fixed in 
10% phosphate buffered formalin and wax embedded.
Staining protocol of 3D ex vivo cultures for optical 
projection tomography 
Large-scale specimen staining for optical projection 
tomography has followed a previously published protocol 
[4]. Briefly, fixed and permebialised preparations were 
incubated with primary antibody to identify the epithelial 
content using rabbit pan-cytokeratin (Cell Signalling), 
and subsequently with a fluorescein-conjugated secondary 
antibody (Invitrogen). The preparation was mounted in 1% 
low melting agarose and dehydrated in 100% Methanol for 
24 h. The specimen was cleared in BABB solution (1:2 
Benzyl alcohol, Benzyl benzoate) for 24 h and scanned 
using the Optical Projection Tomograph (Bioptonics 
3001M). Both target and auto-fluorescence were captured 
using a GFP+ filter and GFP1 filter respectively.
Immunohistochemistry
Antigen retrieval for all staining was performed 
using sodium citrate buffer (18 μM Citric Acid, 82 μM 
sodium citrate, pH 6.0). Standard immunohistochemistry 
protocol was performed using the REAL EnVision 
mouse or rabbit kit (Dako), according to manufacturer’s 
instructions.  Primary antibodies used were: β-catenin, BD 
#610153, Mouse, 1:500; CD44, AbD serotec #MCA2504, 
Mouse, 1:10,000; Cleaved caspase-3, Cell Signaling 
#9661, 1:400; Cyclin D1, Dako #M3635, Rabbit 1:100 
E-cadherin (intracellular), BD #610181, Mouse, 1:1500; 
G3BP2, Sigma #HPA018304, Rabbit, 1:5000; Ki67, Dako 
#M7240, Mouse, 1:400; phosphorylated STAT3 (Ser727), 
Eurogentec, #65367, Rabbit, 1:200-1:600; Rac1, GeneTex, 
#GTX100761, Rabbit, 1:100-1:200.
Categorisation of effects on explant outgrowths ex 
vivo
After 14 d of treatment with either Rac inhibitior 
(EHT 1864) or STAT3 inhibitor (Stattic), all preparations 
were inspected using live microscopy. Cell invasion from 
the original tumour explant into the surrounding collagen 
is typically observed after 6-8 d from start of culture [5]. 
At each experimental time point, media was removed and 
cellular outgrowths ware determined by light microscopy 
(x10 magnification). The viability of outgrowths was 
confirmed subsequently using H&E sections from the 
fixed preparations.
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